- Home
- RGNX vs KROS Comparison
RGNX vs KROS Comparison
Compare RGNX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGNX | KROS |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 761.9M | 655.9M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RGNX | KROS |
|---|---|---|
| Price | $14.94 | $18.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $30.78 | $23.00 |
| AVG Volume (30 Days) | ★ 706.5K | 480.1K |
| Earning Date | 03-12-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | $161,318,000.00 | ★ $246,718,000.00 |
| Revenue This Year | $133.58 | $6,924.79 |
| Revenue Next Year | $45.08 | N/A |
| P/E Ratio | ★ N/A | $11.70 |
| Revenue Growth | 91.30 | ★ 37798.31 |
| 52 Week Low | $5.04 | $9.12 |
| 52 Week High | $15.84 | $22.55 |
Technical Indicators
Market Signals| Indicator | RGNX | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 47.87 |
| Support Level | $13.40 | $18.33 |
| Resistance Level | $15.31 | $19.67 |
| Average True Range (ATR) | 0.96 | 0.75 |
| MACD | -0.08 | -0.11 |
| Stochastic Oscillator | 70.71 | 50.34 |
Price Performance
Historical ComparisonAbout RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.